Effectiveness of Using the Calendar Method of Self-Monitoring Medication Side Effects in SLE Patients
DOI:
Abstract
An autoimmune rheumatic disease that produces widespread inflammation, affecting organs or systems in the body is known as Systemic Lupus Erythematosus (SLE). In a previous study, data were obtained from the results of an analysis based on the Naranjo algorithm obtained were that most respondents fell into the Probable category (Most likely to occur ROM) as many as 14 respondents or 35%, followed by the Definite category (Definite ROM occurs) as many as 12 respondents or 30%. Then the Possible category (Possible ROM occurs) as many as 9 respondents or 22.5% and finally the No ES category as many as 5 respondents or 12.5%. The type of research used was quantitative research with experimental methods through a pretest-posttest control group design by taking a sample and then conducting a pretest first to find out which samples are classified namely interventions experiencing side effects, interventions with no side effects, controls experiencing side effects and controls with no side effects. Based on the results of the Wilcoxon analysis with a p value <0.05, it states that the calendar has an effect on reducing the incidence of side effects in patients. Mann Whitney test showing a p value of 0.000 smaller than 0.05, so it can be interpreted that there are significant differences in side effects in patients with Systemic Lupus Erythematosus (SLE) in the intervention group and control group. The provision of functional calendar media is effective for reducing the incidence of side effects in taking Systemic Lupus Erythematosus (SLE) drugs.
Downloads
Views : 168
Downloads : 160
References
References
Iwan Yuwindry and Noval, “Gambaran Kejadian Efek Samping Pada Penggunaan Obat Off Label Pasien Lupus,” Borneo J. Pharmascientech, vol. 4, no. 1, pp. 12–21, 2020, doi: 10.51817/bjp.v4i1.273.
I. Yuwindry, U. S. Mulia, J. P. Nomor, P. Luar, K. B. Timur, and K. Selatan, “Pengaruh Efek Samping Obat Off Label terhadap Kualitas Hidup Pasien Lupus di RSUD Ulin Banjarmasin The Consequence of the Side Effects of Off Label Drugs on the Quality of Life of Lupus Patients at Ulin Hospital Banjarmasin,” vol. 8, no. 2, pp. 54–61, 2021.
I. Yuwindry, Yusri, and H. H. Tangkas, “Study of the Impact of Side Effects of Using Off-Label Drugs in Patients with Systemic Lupus Erythematosus on Health Costs,” J. Adv. Med. Pharm. Sci., vol. 2, no. 1, pp. 25–28, 2023, doi: 10.36079/lamintang.jamaps-0201.529.
InfoDatin Pusat Data dan Informasi Kementerian Kesehatan RI, “Situasi Lupus di Indonesia,” Pusat Data dan Informasi Kementerian Kesehatan RI. pp. 1–6, 2017.
F. Baroroh and S. S. Fathonah, “Biaya Medik Langsung Terapi Hipertensi Pasien Rawat Jalan Di Rumah Sakit X Yogyakarta,” J. Farm. Sains dan Prakt., vol. 3, no. 2, pp. 6–13, 2017, doi: 10.31603/pharmacy.v3i2.1724.
J. G. Putri and A. B. Wisan, “Efek Samping Terapi Kortikosteroid Sistemik Jangka Panjang pada Pasien Lupus Erimatosus Sistemik dan Tatalaksana Dermatologi,” Cermin Dunia Kedokt., vol. 47, no. 2, pp. 127–129, 2020.
I. Yuwindry et al., “Efektivitas Penggunaan Media Kalender Fungsional terhadap Peningkatan Kepatuhan Penggunaan Obat Secara Mandiri pada Pasien Hipertensi The Effectiveness of Using Functional Calendar Media on Improving Compliance with Drug Use in Hypertension Patients,” vol. 8, no. 1, pp. 21–26, 2021.
I. Yuwindry, Yusri, and H. H. Tangkas, “Kajian Dampak Efek Samping Penggunaan Obat Off Label Pada Pasien Sistemik Lupus Eritematosus (Sle) Terhadap Biaya Kesehatan,” J. Ilm. Ibnu Sina Ilmu Farm. dan Kesehat., vol. 8, no. 2, pp. 176–184, 2023.
D. A. C. Frattarelli, J. L. Galinkin, T. P. Green, T. D. Johnson, K. A. Neville, I. M. Paul, and J. N. van den Anker, "Off-label use of drugs in children," Pediatrics, vol. 128, no. 3, pp. 563-567, 2006.
P. Nash and R. Nair, "Advances in Systemic Lupus Erythematosus: New Treatment Options and Emerging Therapies," Journal of Autoimmunity, vol. 113, p. 102501, 2023.
D. P. D’Cruz and M. A. Khamashta, "Treatment Strategies for Systemic Lupus Erythematosus: A Comprehensive Review," Lupus Science & Medicine, vol. 10, no. 1, pp. e000732, 2023.
J. Manson and S. Gupta, "Off-Label Drug Use in Systemic Lupus Erythematosus: An Overview of Current Practices and Future Directions," Clinical Reviews in Allergy & Immunology, vol. 65, no. 3, pp. 456-467, 2023.
S. J. Ellis and M. R. Ward, "Adverse Drug Reactions: Identifying High-Risk Populations and Common Drug Culprits," Journal of Clinical Pharmacology, vol. 63, no. 2, pp. 200-210, 2023.
A. Patel and L. S. Brooks, "Understanding and Managing Drug Side Effects: A Comprehensive Review," Pharmacotherapy, vol. 43, no. 4, pp. 456-471, 2023.
H. Zhang, T. Wilson, and K. M. Lee, "Mechanisms of Drug-Induced Adverse Events and Their Impact on Patient Outcomes," European Journal of Clinical Medicine, vol. 15, no. 1, pp. 22-34, 2023.
J. M. Hall and D. L. Jenkins, "Classification of Adverse Drug Effects: Type A and Type B Reactions," Journal of Pharmacology and Therapeutics, vol. 67, no. 5, pp. 789-798, 2023.
R. S. Hughes and E. T. Miller, "Understanding Type A and Type B Adverse Drug Reactions: Implications for Clinical Practice," Clinical Pharmacology and Therapeutics, vol. 114, no. 3, pp. 489-497, 2023.
M. B. Johnson and A. K. Smith, "Dose-Dependent versus Individualized Adverse Drug Reactions: A Review of Recent Findings," Drug Safety, vol. 46, no. 1, pp. 15-25, 2023.
